CA2833775A1 - Proteasome inhibitors and processes for their preparation, purification and use - Google Patents

Proteasome inhibitors and processes for their preparation, purification and use Download PDF

Info

Publication number
CA2833775A1
CA2833775A1 CA2833775A CA2833775A CA2833775A1 CA 2833775 A1 CA2833775 A1 CA 2833775A1 CA 2833775 A CA2833775 A CA 2833775A CA 2833775 A CA2833775 A CA 2833775A CA 2833775 A1 CA2833775 A1 CA 2833775A1
Authority
CA
Canada
Prior art keywords
formula
optionally substituted
boronic ester
compound
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2833775A
Other languages
English (en)
French (fr)
Inventor
Roger P. Bakale
John P. Mallamo
Renee Caroline Roemmele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of CA2833775A1 publication Critical patent/CA2833775A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2833775A 2011-06-22 2012-06-21 Proteasome inhibitors and processes for their preparation, purification and use Abandoned CA2833775A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161499962P 2011-06-22 2011-06-22
US61/499,962 2011-06-22
PCT/US2012/043485 WO2012177835A1 (en) 2011-06-22 2012-06-21 Proteasome inhibitors and processes for their preparation, purification and use

Publications (1)

Publication Number Publication Date
CA2833775A1 true CA2833775A1 (en) 2012-12-27

Family

ID=46395746

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2833775A Abandoned CA2833775A1 (en) 2011-06-22 2012-06-21 Proteasome inhibitors and processes for their preparation, purification and use

Country Status (6)

Country Link
US (1) US20140121182A1 (enExample)
EP (1) EP2723751A1 (enExample)
JP (1) JP5944986B2 (enExample)
CA (1) CA2833775A1 (enExample)
MX (1) MX2013015308A (enExample)
WO (1) WO2012177835A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2925935A1 (en) * 2013-10-03 2015-04-09 Millennium Pharmaceuticals, Inc. Method for the prophylaxis or treatment of systemic lupus erythematosus and/or lupus nephritis
US9546928B2 (en) 2014-05-30 2017-01-17 General Electric Company Methods for producing strain sensors on turbine components
US10415964B2 (en) * 2014-05-30 2019-09-17 General Electric Company Methods for producing passive strain indicator on turbine components
MA41505A (fr) * 2015-02-11 2017-12-19 Millennium Pharm Inc Nouvelle forme cristalline d'un inhibiteur de protéasome
CZ2015233A3 (cs) 2015-04-03 2016-10-12 Zentiva, K.S. Způsob přípravy Ixazomib citrátu
CZ2015253A3 (cs) 2015-04-15 2016-10-26 Zentiva, K.S. Nové formy Ixazomib citrátu
WO2016205790A2 (en) * 2015-06-19 2016-12-22 Hanlin Scientific, Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
CN106608883A (zh) * 2015-10-21 2017-05-03 北京大学 蛋白酶体抑制剂mln9708的合成方法
CN106986884A (zh) * 2016-01-20 2017-07-28 成都贝斯凯瑞生物科技有限公司 一种高效的高纯度含硼化合物制备方法
CN105732683B (zh) * 2016-03-25 2018-10-16 南京林业大学 一类羧酸与α氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
CZ2016204A3 (cs) 2016-04-08 2017-11-01 Zentiva, K.S. Formulace Ixazomib citrátu formy 3
CN107400142B (zh) * 2016-05-19 2019-11-19 成都奥璟生物科技有限公司 一种硼酸和硼酸酯类化合物及其应用
WO2018133661A1 (zh) * 2017-01-23 2018-07-26 成都奥璟生物科技有限公司 一种新的硼酸衍生物及其药物组合物
CN109305980B (zh) 2017-07-28 2022-10-11 成都奥璟生物科技有限公司 一种硼酸酯化合物、其合成方法及其用途
BR112021001963B1 (pt) * 2018-08-02 2024-02-15 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Compostos de borato de um derivado de azetidina, composição farmacêutica que compreende os ditos compostos e uso dos mesmos para prevenção ou tratamento de mieloma múltiplo

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
RS53259B (sr) 2004-03-30 2014-08-29 Millennium Pharmaceuticals Inc. Sinteza bortezomiba
EP2178888B1 (en) * 2007-08-06 2012-07-04 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
HRP20150592T4 (hr) 2008-06-17 2025-02-14 Millennium Pharmaceuticals, Inc Organoborni esterski spojevi i njihove farmaceutske kompozicije
EP2238973A1 (en) * 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors

Also Published As

Publication number Publication date
JP2014520155A (ja) 2014-08-21
US20140121182A1 (en) 2014-05-01
MX2013015308A (es) 2014-05-20
JP5944986B2 (ja) 2016-07-05
EP2723751A1 (en) 2014-04-30
WO2012177835A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
JP5944986B2 (ja) プロテアソーム阻害剤、ならびにそれらの調製、精製、および使用のためのプロセス
AU2010341530B2 (en) Proteasome inhibitors and processes for their preparation, purification and use
CN113784957B (zh) Nlrp3炎性小体抑制剂
TWI567070B (zh) 結晶n-﹝5-(胺磺醯基)-4-甲基-1,3-噻唑-2-基﹞-n-甲基-2-﹝4-(2-吡啶基)苯基﹞乙醯胺甲烷磺酸單水化物、其組合物、其用途以及包括其的醫藥組成物
CA2744231A1 (en) Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
CA2829993A1 (en) Antimicrobial agents
Vedejs et al. Asymmetric transformation in boron ate complexes of amino acids
US8497374B2 (en) Process for preparing and purifying bortezomib
CA2996308A1 (en) Prodrugs of chlorokynurenines
MX2014007009A (es) Formas solidas de clorhidrato de (1r,4r)-6´-fluoro-n,n-dimetil-4-f enil-4´,9´-dihidro-3´h-espiro-[ciclohexano-1,1´-pirano[3,4,b]indo l]-4-amina.
WO2014097306A1 (en) Stable and pure polymorphic form of bortezomib
JP2023548368A (ja) 複素環式メタノン化合物及びそのアザビシクロ中間体の製造方法
US8912343B2 (en) Solid forms of (1r,4r)-6′-fluoro-(N, N-dimethyl)-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and sulfuric acid
CN118994222B (zh) 一种4-硼-10酸-l-苯丙氨酸的中间体的制备方法及应用
KR20160037031A (ko) 라세믹 또는 광학적으로 활성이 있는 D 또는 L-α-글리세로포스포릴콜린 고체의 제조방법
CN112823152A (zh) 用于制备布罗莫结构域抑制剂的方法
CA2933371A1 (en) Polymorphic forms of a steroid-like compound and methods for the preparation and use thereof
WO2023095162A1 (en) Cocrystal of roxadustat and nicotinamide
CN102442974B (zh) 樟脑衍生化合物及其制造方法与应用
HK40045554A (en) Process for the preparation of bromodomain inhibitor
WO2007068324A1 (en) Polymorph of atomoxetine hydrochloride in crystalline form
NZ621615B2 (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
HK1196018A (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
HK1196018B (en) N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180621